Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Mehr anzeigen
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Jan. 2, 2025 LAUSANNE, Switzerland, Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma PR Newswire LAUSANNE...
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell...
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular...
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 6, 2024 Company to host corporate update webcast to share results on December 11...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Dec. 2, 2024 LAUSANNE, Switzerland, Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.128 | -6.852248394 | 1.868 | 1.9 | 1.675 | 541285 | 1.77863033 | CS |
| 4 | -0.33 | -15.9420289855 | 2.07 | 2.195 | 1.675 | 710655 | 1.93960654 | CS |
| 12 | -1.17 | -40.206185567 | 2.91 | 3.49 | 1.675 | 937393 | 2.45943069 | CS |
| 26 | -2.26 | -56.5 | 4 | 4.1 | 1.675 | 615802 | 2.66697323 | CS |
| 52 | -0.15 | -7.93650793651 | 1.89 | 6.04 | 1.675 | 692747 | 3.3138675 | CS |
| 156 | -15.19 | -89.7223862965 | 16.93 | 17.89 | 0.359908 | 534203 | 3.59744156 | CS |
| 260 | -28.26 | -94.2 | 30 | 56.5899 | 0.359908 | 430379 | 8.94679918 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
